Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients
L Calza, R Manfredi, F Chiodo - Journal of Antimicrobial …, 2004 - academic.oup.com
Highly active antiretroviral therapy (HAART) has had a significant impact on the natural
history of human immunodeficiency virus (HIV) infection, leading to a remarkable decrease …
history of human immunodeficiency virus (HIV) infection, leading to a remarkable decrease …
Low CD4+ T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study
KA Lichtenstein, C Armon, K Buchacz… - Clinical Infectious …, 2010 - academic.oup.com
Background. Traditional cardiovascular disease (CVD) risk factors, human
immunodeficiency virus (HIV) infection, and antiretroviral (ARV) agents have been …
immunodeficiency virus (HIV) infection, and antiretroviral (ARV) agents have been …
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials
A Hill, J van der Lugt, W Sawyer, M Boffito - Aids, 2009 - journals.lww.com
Background: Ritonavir has been evaluated at boosting doses of 50–800 mg daily with seven
protease inhibitors: amprenavir, atazanavir, darunavir, indinavir, lopinavir, saquinavir and …
protease inhibitors: amprenavir, atazanavir, darunavir, indinavir, lopinavir, saquinavir and …
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
M Johnson, B Grinsztejn, C Rodriguez, J Coco… - Aids, 2005 - journals.lww.com
Objective: To evaluate atazanavir/ritonavir (ATV/RTV)(300/100 mg) once daily,
atazanavir/saquinavir (ATV/SQV)(400/1200 mg) once daily, and lopinavir/ritonavir …
atazanavir/saquinavir (ATV/SQV)(400/1200 mg) once daily, and lopinavir/ritonavir …
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M Johnson, B Grinsztejn, C Rodriguez, J Coco… - Aids, 2006 - journals.lww.com
Background: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV)
demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir …
demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir …
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens
K Anastos, D Lu, Q Shi, PC Tien… - JAIDS Journal of …, 2007 - journals.lww.com
Background: The effects of HIV infection, highly active antiretroviral therapy (HAART), and
specific antiretroviral agents on lipoproteins in women are not well described. Methods: In a …
specific antiretroviral agents on lipoproteins in women are not well described. Methods: In a …
Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study
Swiss HIV Cohort Study, J Young, R Weber… - Antiviral …, 2005 - journals.sagepub.com
Background Blood lipid abnormalities in patients on highly active antiretroviral therapy
(HAART) have been associated with exposure to protease inhibitors (PIs), particularly …
(HAART) have been associated with exposure to protease inhibitors (PIs), particularly …
Lipid profile in HIV/AIDS patients in Nigeria
OO Adewole, S Eze, YE Betiku, E Anteyi, I Wada… - African health …, 2010 - ajol.info
Introduction: Alterations of serum lipid profiles have been reported widely among Human
Immuno deficiency Virus (HIV) positive patients on Highly Active Anti Retroviral Therapy …
Immuno deficiency Virus (HIV) positive patients on Highly Active Anti Retroviral Therapy …
Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia …
Panel de Expertos de GeSIDA y Plan Nacional … - … y Microbiología Clínica, 2011 - Elsevier
La actualización de estas recomendaciones de tratamiento antirretroviral del adulto se han
consensuado por un panel de expertos del Grupo de Estudio de Sida y del Plan Nacional …
consensuado por un panel de expertos del Grupo de Estudio de Sida y del Plan Nacional …
Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in …
C Lagathu, JP Bastard, M Auclair, M Maachi… - Antiviral …, 2004 - journals.sagepub.com
Objective The lipodystrophy syndrome is a major adverse effect of highly active antiretroviral
therapy (HAART), associated with altered circulating levels and adipose tissue mRNA …
therapy (HAART), associated with altered circulating levels and adipose tissue mRNA …